SEARCH THE OnBioVC DATABASE:
OnBioVC NEWS:

- OnBioVC 4Q11 Trend Analysis, now available
- OnBioVC 1Q12 Trend Analysis, coming soon

15

Sep

2009

Novacta Biosystems, Ltd.: Series B $21.6M

Posted in I - Series B, Q - 3Q09, R - INTERNATIONAL, X - Antibacterial, X - Antiinfective

Novacta Biosystems (United Kingdom) a pre-clinical stage biopharmaceutical company developing anti-invectives against C. difficile, closed a $21.6M Series B financing. Participants include Celtic Pharma.

Venture Capital Investors
5AM Ventures Advanced Technology Ventures Alta Partners Amgen Ventures ARCH Venture Partners Bay City Capital Bessemer Venture Partners Canaan Partners Clarus Ventures Delphi Ventures Domain Associates Edmond de Rothschild Investment Partners Flagship Ventures Forbion Capital Partners HBM Bioventures Healthcare Ventures HLM Venture Partners Interwest Partners Investor Growth Capital Kaiser Permanente Ventures Kleiner Perkins Latterell Venture Partners Lilly Ventures Mohr Davidow Ventures MPM Capital New Enterprise Associates New Leaf Venture Partners Novartis Venture Fund Novo Ventures OrbiMed OVP Venture Partners Pappas Ventures Polaris Venture Partners Prospect Venture Partners Quaker BioVentures Sanderling Ventures Sofinnova Partners Sofinnova Ventures SR One SV Life Sciences Third Rock Ventures TPG Biotech TVM Capital Venrock Versant Ventures

OnBioVC Friends

FluidicMEMES
IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners